reports
- Dave Nicoski
- Ross LaDuke
PBF PBF ENERGY INC. CLASS A
LEN LENNAR CORPORATION CLASS A
GPRE GREEN PLAINS INC.
GBCI GLACIER BANCORP INC.
FFIC FLUSHING FINANCIAL CORP.
DVN DEVON ENERGY CORPORATION
DECK DECKERS OUTDOOR CORPORATION
CRL CHARLES RIVER LABORATORIES INTERNATIONAL INC.
CNO CNO FINANCIAL GROUP INC.
CBU COMMUNITY BANK SYSTEM INC.
BIIB BIOGEN INC.
BC BRUNSWICK CORPORATION
HP HELMERICH & PAYNE INC.
PVH PVH CORP.
TTC TORO COMPANY
HOG HARLEY-DAVIDSON INC.
WGO WINNEBAGO INDUSTRIES INC.
APLS APELLIS PHARMACEUTICALS
PRPL PURPLE INNOVATION
GRWG GROWGENERATION
DCOM DIME COMMUNITY BANCSHARES INC
APA APA CORPORATION
AMR ALPHA METALLURGICAL RESOURCES INC
BBWI BATH & BODY WORKS INC
CIVI CIVITAS RESOURCES INC
BORR BORR DRILLING LTD
MBC_w MASTERBRAND INC
NE NOBLE CORP (NEW)
FTREV FORTREA HOLDINGS INC.
Cytokinetics to Participate in September Investor Conferences
Cytokinetics to Participate in September Investor Conferences SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in September: Citi’s 2025 BioPharma Back to School Conference: Fireside chat on Tuesday, September 2, 2025 at 2:30 PM Eastern Time in Boston, MA.2025 Wells Fargo Healthcare Conference: Fireside chat on Wednesday, September 3, 2025 at 11:00 AM Eastern Time in Everett, MA.Cantor Global Healthcare Conference 2025:...
Cytokinetics Announces Five Presentations Related to Aficamten at the ...
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025 Positive Results from MAPLE-HCM to be Shared in Hot Line Presentation Late Breaking Clinical Science Session to Present Incidence and Impact of Atrial Fibrillation Across Three Clinical Trials of Aficamten in Obstructive Hypertrophic Cardiomyopathy Company to Host Investor Event and Webcast Tuesday September 2, 2025, at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced ...
Cytokinetics Names Jim Daly to Board of Directors
Cytokinetics Names Jim Daly to Board of Directors SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience with particular expertise in commercialization to the Company’s Board of Directors. “Jim has longstanding expertise leading commercial launches of innovative therapies, coupled with extensive Board experience guiding later-stage, global biopharma companies,...
Ligand to Participate in September Investor Conferences
Ligand to Participate in September Investor Conferences JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Citi 20th Annual BioPharma Conference (Boston): Management will participate in a fireside chat on September 3, 2025 at 11:15 a.m. ET. H.C. Wainwright 27th Annual Global Investment Conference (New York): Management will present on September 9, 2025 at 1:00 p.m. ET. Ligand ma...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 563...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 15, 2025 it granted stock options to purchase an aggregate of 105,169 shares of common stock and 70,879 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 46 employees, whose employment commenced in July and August 2025 as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the fir...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Speculative Areas Still Leading; Staying Bullish We have discussed since late-July how the S&P 500 (SPX) had not closed below its 20-day MA for three months, but that even when it does, "all we would expect to happen is for a new, less-steep uptrend to form." That is precisely what has happened after the SPX finally lost its 20-day MA (for one whole day) on 8/1/25, only to get back to all-time highs last week. Therefore, we remain near-term bullish since our 4/22/25 Compass, and our intermediat...
INSM INSMED INCORPORATED
GPRE GREEN PLAINS INC.
CYTK CYTOKINETICS INCORPORATED
AXSM AXSOME THERAPEUTICS
ACAD ACADIA PHARMACEUTICALS INC.
REX REX AMERICAN RESOURCES CORPORATION
WVE WAVE LIFE SCIENCES
MRUS MERUS B V
BBIO BRIDGEBIO PHARMA
NVAX NOVAVAX INC.
RNA AVIDITY BIOSCIENCES
IREN IRIS ENERGY LTD
ACLX ARCELLX INC
APLD APPLIED BLOCKCHAIN INC
WGMI COINSHARES BITCOIN MINING ETF
KNSA KINIKSA PHARMACEUTICALS INTERNATIONAL PLC
HUT HUT 8 CORP
Ligand Announces Closing of Convertible Senior Notes Offering
Ligand Announces Closing of Convertible Senior Notes Offering JUPITER, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today that it completed its previously announced offering (the “offering”) of 0.75% convertible senior notes due 2030 (the “notes”). The aggregate principal amount of the notes sold in the offering was $460.0 million, which includes the purchase of an additional $60.0 million aggregate principal amount of notes by the initial purchasers pursuant to the full exercise of the initial purchasers’ option to purcha...
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offe...
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes due 2030 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Ligand also granted the initial purchasers of the notes (the “initial purchasers...
Ligand Announces Proposed Offering of $400 Million of Convertible Seni...
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $400.0 million aggregate principal amount of convertible senior notes due 2030 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), subject to market conditions and other factors. Ligand also expec...
- Jonathan Moreland
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TFX TELEFLEX INCORPORATED
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
SHBI SHORE BANCSHARES INC.
PNFP PINNACLE FINANCIAL PARTNERS INC.
OPK OPKO HEALTH INC.
NSP INSPERITY INC.
NPO ENPRO INDUSTRIES INC.
MTDR MATADOR RESOURCES COMPANY
MMLP MARTIN MIDSTREAM PARTNERS L.P.
LLY ELI LILLY AND COMPANY
KMPR KEMPER CORPORATION
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
EIG EMPLOYERS HOLDINGS INC.
CNOB CONNECTONE BANCORP INC.
CHTR CHARTER COMMUNICATIONS INC. CLASS A
CHD CHURCH & DWIGHT CO. INC.
CDXS CODEXIS
ARW ARROW ELECTRONICS INC.
AMH AMERICAN HOMES 4 RENT CLASS A
CIVB CIVISTA BANCSHARES
OLN OLIN CORPORATION
ASUR ASURE SOFTWARE INC
BRO BROWN & BROWN INC.
CYRX CRYOPORT INC.
FTV FORTIVE CORP.
CLAR CLARUS CORPORATION
A2H9KJ NEO PERFORMANCE MATERIAL
OSPN ONESPAN
FXNC FIRST NATIONAL CORP. OF VIRGINIA
TROX TRONOX HOLDINGS PLC
MEC MAYVILLE ENGINEERING
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
XRX XEROX HOLDINGS CORPORATION
PINE ALPINE INCOME PROPERTY TRUST
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
LRMR LARIMAR THERAPEUTICS INC
THRY THRYV HOLDINGS
DLHC DALEIGH HOLDINGS CORP
INTA INTAPP INC
PTLO PORTILLOS INC
BRBR BELLRING BRANDS INC
AUB ATLANTIC UNION BANKSHARES CORP
AURX NUO THERAPEUTICS
OI INC.
SIRI OWENS ILLINOIS INC.
XELB SIRIUS XM HLDGS INC NEW
MUSA XCEL BRANDS INC.
LNW METALS USA HOLDINGS CORP.
LIGHT & WONDER INC.
Cytokinetics Reports Second Quarter 2025 Financial Results and Provide...
Cytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update Regulatory Reviews of Aficamten for Obstructive HCM Progressing in U.S., E.U. and China; Late-Cycle Meeting with U.S. FDA Scheduled for September Ahead of December 26, 2025 PDUFA Date Primary Results from MAPLE-HCM to be Presented in a Hot Line Session at the European Society of Cardiology Congress 2025 ~$1.0 Billion in Cash, Cash Equivalents and Investments as of June 30, 2025 SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK)...
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidan...
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million) and adjusted earnings per diluted share1 increased to $6.70 - $7.00 (previously $6.00 - $6.25) Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended Jun...
- Jonathan Moreland
EIG EMPLOYERS HOLDINGS INC.
CNOB CONNECTONE BANCORP INC.
CIVB CIVISTA BANCSHARES
CZWI CITIZENS COMMUNITY BANCORP
MBIN MERCHANTS BANCORP
CHMG CHEMUNG FINANCIAL CORP.
SONO SONOS
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
XRX XEROX HOLDINGS CORPORATION
THRY THRYV HOLDINGS
PRME PRIME MEDICINE INC
XELB XCEL BRANDS INC.
Gran Tierra Energy Acquires Strategic Assets in Ecuador’s Oriente Basi...
Gran Tierra Energy Acquires Strategic Assets in Ecuador’s Oriente Basin CALGARY, Alberta, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”) (NYSE American:GTE)(TSX:GTE)(LSE:GTE) announced that its indirect wholly owned subsidiaries, Gran Tierra Energy Ecuador 1 GmbH and Gran Tierra Energy Ecuador 2 GmbH, have entered into definitive agreements to acquire all of GeoPark Ecuador S.A.’s and Frontera Energy Colombia Corp Sucursal Ecuador’s (the “Sellers”) interests in the Perico and Espejo Blocks (the “Blocks”) and their associated Consortiums (the “Co...
- Jonathan Moreland
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
PNFP PINNACLE FINANCIAL PARTNERS INC.
FFIN FIRST FINANCIAL BANKSHARES INC
CHTR CHARTER COMMUNICATIONS INC. CLASS A
CDXS CODEXIS
CIVB CIVISTA BANCSHARES
CZWI CITIZENS COMMUNITY BANCORP
MBIN MERCHANTS BANCORP
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
CRDF CARDIFF ONCOLOGY INC
JMSB JOHN MARSHALL BANCORP INC
MMC MARSH & MCLENNAN COMPANIES INC.
Gran Tierra Energy Inc. Reports Second Quarter 2025 Results & Another ...
Gran Tierra Energy Inc. Reports Second Quarter 2025 Results & Another Quarter of Record Production Achieved Record Total Company Average Quarterly Production of 47,196 boepdFunds Flow From Operations(1) of $54 million, Adjusted EBITDA(1) of $77 million and Return to Free Cash FlowSigned Mandate Letter for Funding of Up to $200 MillionEntered into Binding Agreement to Exit the UK North Sea Achieved Company Record Total of 32 Million Hours Without a Lost Time InjuryRecorded Operating Costs per boe of $13.42 for the Quarter - the Lowest Since The First Quarter of 2022 CALGARY, Alberta, July ...
Cytokinetics to Announce Second Quarter Results On August 7, 2025
Cytokinetics to Announce Second Quarter Results On August 7, 2025 SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 7, 2025 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics’ website at or ...
Ligand to Report Second Quarter 2025 Financial Results on August 7, 20...
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 JUPITER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, August 7, 2025 Time: 8:30 AM Eastern Time Conference Call:(800) 715-9871 (U.S. & Canada)(646) 307-1963 (International)Conference ID ...
Gran Tierra Energy Inc. Provides Release Date for its 2025 Second Quar...
Gran Tierra Energy Inc. Provides Release Date for its 2025 Second Quarter Results CALGARY, Alberta, July 23, 2025 (GLOBE NEWSWIRE) -- Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”) (NYSE American:GTE)(TSX:GTE)(LSE:GTE) announces that the Company will release its 2025 second quarter financial and operating results on Wednesday July 30, 2025, post-market. Gran Tierra will host its second quarter 2025 results conference call on Thursday, July 31, 2025, at 9:00 a.m. Mountain Time, 11:00 a.m. Eastern Time. How to Participate in the 2025 Second Quarter Conference Call Interested...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.